Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase I trial of INK-128 initiated in multiple myeloma

Dec. 2, 2010

Elara Pharma's new antitumor agent EL-102 inhibits HIF-1-alpha and cellular proliferation

Dec. 2, 2010

PI3K-delta inhibitor XL-499 shows promising preclinical activity

Dec. 2, 2010

Pfizer's phase III axitinib trial in renal cell carcinoma meets primary endpoint

Dec. 1, 2010

Immunovaccine and OncoTherapy Science join to develop cancer vaccine

Dec. 1, 2010

Multikinase inhibitor AI-1008 shows promise to treat chronic myeloid leukemia in preclinical testing

Dec. 1, 2010

GlaxoSmithKline claims new inhibitors of focal adhesion kinase 1

Dec. 1, 2010

Preclinical activity of LY-S6KAKT1 justifies entry into phase I trial as cancer therapy

Dec. 1, 2010

FDA to review Spectrum Pharma's complete response regarding Fusilev sNDA

Nov. 30, 2010

New inhibitors of cell division protein kinase 4 claimed

Nov. 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...